Browse the evidence

Solo biofragmentable magnetic duodenoileostomy (MagDI) creates a partial intestinal bypass that significantly reduces body weight and improves type 2 diabetes markers in patients with mild obesity (BMI 30-35).

This paper describes a new, minimally invasive surgical option for people with mild obesity (BMI 30-35) and type 2 diabetes. Instead of removing part of the stomach, doctors use magnets to connect the upper small intestine (duodenum) to the lower small intestine (ileum). This creates a partial bypass that helps you lose weight and control blood sugar without major surgery or permanent implants. The magnets dissolve and pass naturally after about 3 weeks. While promising, this is a new procedure with limited long-term data, so it should be considered carefully with a specialist.

Tirzepatide may reduce the risk of atherosclerosis progression through lipid-lowering, anti-inflammatory, and improved insulin sensitivity mechanisms, offering cardioprotective benefits beyond glycemic control.

Tirzepatide not only lowers blood sugar and helps with weight loss but may also protect your heart and blood vessels by reducing inflammation and improving lipid levels. This is especially important if you have diabetes and heart disease.

Native gut-produced GLP-1 exerts central anorectic effects via a neuroendocrine signaling mechanism involving the portal vein and vagal afferent nerves, without entering the brain.

Your body naturally produces GLP-1 after eating, which signals fullness to your brain via the vagus nerve. This is a fast, efficient system that doesn't require the hormone to cross into the brain tissue, explaining why synthetic GLP-1 drugs mimic this natural process effectively.

Preclinical evidence indicates that GLP-1 RAs directly improve skeletal muscle quality by reducing intramuscular fat (myosteatosis), enhancing mitochondrial biogenesis, and suppressing inflammatory markers, independent of weight loss.

Animal studies suggest GLP-1 drugs may improve the 'quality' of your muscle cells by boosting mitochondria and reducing inflammation. While this doesn't mean you'll build bigger muscles without exercise, it may help your muscles function better and recover faster, especially if you have diabetes or obesity.

GLP-1 receptor agonists exert direct anabolic and protective effects on skeletal muscle tissue, including promoting myogenesis, enhancing mitochondrial function, and reducing inflammation, which may help preserve muscle quality despite lean mass loss.

The drug may actively help protect muscle quality at a cellular level, but this does not guarantee muscle mass preservation without active lifestyle interventions.

Cerebral CCK acts as a neurotransmitter involved in memory and anxiety regulation, with knockout mice showing memory loss and increased anxiety, while exogenous CCK administration can induce panic attacks.

CCK is not just a gut hormone; it works in the brain to regulate anxiety and memory. While high doses can induce panic, natural CCK signaling may help modulate these states. This highlights the gut-brain axis.

Commercial protein supplements frequently make unauthorized health claims (e.g., 'post-workout recovery', 'muscle growth') that are not supported by EFSA regulations, whereas only specific claims regarding muscle mass increase/maintenance and bone maintenance are legally authorized.

When buying protein supplements in Europe, ignore marketing buzzwords like 'fast recovery' or 'instant growth' on the label. Legally, these are unauthorized. Look for the specific, EFSA-approved phrase: 'Protein contributes to muscle mass increase' or 'maintenance of muscle mass'. If a product claims 'recovery' without this specific phrasing, it is non-compliant with EU regulations.

Obesity-related complications (ORCs) such as hypertension, diabetes, and dyslipidemia are the primary drivers for initiating pharmacological obesity treatment, often delaying preventative care until complications are present and uncontrolled.

If you have obesity, do not wait for complications like high blood pressure or diabetes to seek treatment. The current system often delays medication until these issues arise, but early intervention with Obesity Management Medications (OMMs) can help control these complications and improve quality of life. Discuss preventative treatment with your doctor, especially if you have a family history of these conditions.

Access to obesity treatment in Canada is inequitable, with patients having high socioeconomic status being overrepresented in treatment programs compared to the general population of people with obesity, who are more likely to have lower socioeconomic status.

If you have a lower income, you may face barriers to accessing obesity treatment due to lack of insurance coverage. Advocate for yourself and your community for better access to affordable treatments. There are resources and programs that may help, and discussing financial concerns with your doctor is important.

Gold-standard T2DM medications (metformin, SGLT2 inhibitors, GLP-1 agonists) modulate the redox state of skeletal muscle, potentially restoring metabolic function and insulin sensitivity.

Standard diabetes medications like metformin and GLP-1 agonists do more than lower blood sugar; they also interact with the redox state of your muscles. This interaction may help restore insulin sensitivity, offering a benefit beyond simple glycemic control.

Semaglutide use is associated with oral adverse effects, specifically xerostomia (dry mouth) and hyposalivation, likely due to prolonged GLP-1 receptor activation disrupting salivary gland signaling.

If you are taking semaglutide and experience persistent dry mouth, do not assume it is solely due to dehydration. The drug's prolonged action on salivary glands can reduce saliva production directly. Consult your provider for preventive oral care strategies to manage this side effect.

Patients often learn about semaglutide and tirzepatide from social media and support groups rather than healthcare providers, who act as 'gatekeepers' rather than initial educators.

If you are interested in semaglutide or tirzepatide, do not assume your doctor will bring it up. You likely learned about it from social media or friends. Bring this information to your appointment, as providers may not be the initial source of this information but are necessary for safe access.

Preoperative use of GLP-1 and GLP-1/GIP receptor agonists significantly reduces surgical site infections, wound dehiscence, and thromboembolic events in patients undergoing elective hernia repair.

If you are scheduled for hernia surgery and take GLP-1 drugs like Ozempic or Mounjaro, do not stop them abruptly without talking to your surgical team. Recent data shows they actually lower your risk of infection and blood clots. Your doctors can use a simple ultrasound on your stomach before anesthesia to check if it's safe to proceed, potentially saving you from stopping a medication that is helping your overall health.

Tirzepatide use is strongly associated with a high frequency of dosing errors, particularly incorrect dose administration, which increases significantly over time and correlates with strong statistical safety signals.

If you are using tirzepatide, be aware that dosing errors are the most common side effect reported. The once-weekly schedule and mandatory dose increases can be confusing. Use a calendar or app to track your injections and strictly follow the titration steps to avoid mistakes.

Tirzepatide is associated with injection-site reactions, particularly pain, which are consistent with the class of GLP-1/GIP agonists and are typically mild and transient.

Injection site pain is a common side effect of tirzepatide. It is usually mild and goes away. Proper injection technique and counseling can help reduce this discomfort and help you stick with your treatment.

Gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, are frequent side effects of tirzepatide, particularly during initiation and titration phases.

GI side effects like nausea and diarrhea are common with tirzepatide, especially when starting or increasing the dose. Talk to your doctor about managing these symptoms with diet changes or medication to help you stay on treatment.

Other protein supplements (soy, casein, pea, rice, etc.) do not show statistically significant differences in muscle strength or fat-free mass gains compared to placebo in healthy adults undergoing resistance training.

If you are using other protein supplements like soy, casein, or pea protein, they may not provide significant additional benefits for muscle strength or mass gains compared to a placebo. Focus on collagen or whey if you want to maximize your results.

Targeting endogenous enteroendocrine cell (EEC) secretion to mimic postprandial hypersecretion of GLP-1 and other GI hormones offers a potential treatment for obesity and type 2 diabetes that avoids the side effects of exogenous GLP-1-based drugs.

Current research suggests that stimulating your gut to release its own GLP-1 (perhaps through specific nutrients or future drugs) might help with weight loss and blood sugar control without the nausea or nutrient malabsorption seen with current GLP-1 injections. This is still experimental.

GLP-1 receptor agonist pharmacotherapy in older adults causes significant loss of lean skeletal muscle mass (approx. 26-40% of total weight lost), which independently predicts adverse outcomes including mortality, functional decline, and frailty.

If you are an older adult using GLP-1 medications, do not focus solely on the number on the scale. The medication causes you to lose muscle along with fat, which can lead to frailty and higher mortality. You must actively counteract this by combining your medication with resistance exercise and adequate protein intake to preserve your muscle mass.

Semaglutide induces adipose tissue remodeling in Type 2 Diabetes by promoting mitochondrial biogenesis, inducing beige adipocyte programming, and reducing visceral adiposity, leading to improved systemic insulin sensitivity and reduced ectopic fat deposition.

For individuals with T2DM or obesity, semaglutide offers benefits that go beyond simple weight loss. It actively remodels fat tissue, particularly visceral fat, making it more metabolically active and less inflammatory. This leads to improved insulin sensitivity and reduced liver fat, which are critical for long-term metabolic health. The medication is taken once weekly, with doses tailored to whether the goal is managing diabetes (up to 1.0 mg) or weight loss (up to 2.4 mg).

Tirzepatide promotes sustained improvements in skeletal muscle mitochondrial respiration and ATP production under lipotoxic conditions, whereas semaglutide and cagrilintide cause transient suppression that resolves over time.

If you are using incretin-based therapies like tirzepatide, this in vitro evidence suggests your muscle cells may become more efficient at producing energy over time, even under metabolic stress. While other drugs in this class (semaglutide, cagrilintide) show temporary dips in mitochondrial function, tirzepatide appears to enhance it. This supports the importance of resistance training to leverage these cellular adaptations for maintaining muscle quality.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a signal for tumorigenesis, specifically thyroid and pancreatic cancers, with risk profiles varying significantly by patient age, sex, and body weight.

If you are considering or using a GLP-1 medication (like Ozempic or Wegovy), be aware that there is a detected signal for thyroid and pancreatic tumors in large-scale reporting databases. This risk is not uniform: it appears more frequently in women (thyroid) and older men (pancreas). You should discuss your specific age, sex, and family history with your doctor to weigh these potential risks against the significant benefits of blood sugar and weight management.

Postmarketing reports of neoplasms are higher for GLP-1 RAs compared to non-GLP-1 agents, but remain rare relative to overall exposure.

While postmarketing reports of neoplasms are higher for GLP-1 RAs, they are still rare. The benefits of weight loss and mortality reduction likely outweigh this small risk for most patients.

Semaglutide is associated with a higher incidence of symptomatic gastrointestinal adverse events compared to dulaglutide in the context of emergency exposures.

If you experience severe nausea or vomiting on semaglutide, talk to your doctor. They might switch you to a different GLP-1 medication, like dulaglutide, which may have fewer gastrointestinal side effects for you.